

March 19, 2019

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

**Code: 532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: CADILAHC**

**Re.: Press Release.**

Dear Sir / Madam,

Please find enclosed a copy of press release dated March 19, 2019 titled "Zydus receives final approval from the USFDA for Acyclovir Ointment".

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**



**DHAVAL N. SONI**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus receives final approval from the USFDA for Acyclovir Ointment**

*Ahmedabad, 19 March 2019*

Zydus Cadila has received the final approval from the USFDA to market Acyclovir Ointment USP (US RLD – Zovirax<sup>®</sup>), 5%. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

Acyclovir is an antiviral drug which stops the growth of certain viruses. This medication is used to treat the first outbreak of genital herpes infection. It is also used to treat non-life-threatening herpes infections of the skin and around the mouth (cold sores) in people with a weakened immune system.

The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*